Bristol-Myers Squibb Company (BMY)

53.87
NYSE : Health Care
Prev Close 53.87
Day Low/High 0.00 / 0.00
52 Wk Low/High 53.76 / 77.12
Avg Volume 11.62M
Exchange NYSE
Shares Outstanding 1.67B
Market Cap 92.05B
EPS 0.90
P/E Ratio 19.75
Div & Yield 1.52 (2.80%)

Latest News

Jim Cramer's Top Takeaways: Thor Industries, e.l.f. Beauty, Bristol-Myers Squibb

Jim Cramer's Top Takeaways: Thor Industries, e.l.f. Beauty, Bristol-Myers Squibb

Cramer says Thor Industries does everything right and Bristol-Myers should be held for the long term.

Jim Cramer's 'Mad Money' Recap: These Fast-Growth Companies Are Hot Again

Jim Cramer's 'Mad Money' Recap: These Fast-Growth Companies Are Hot Again

Cramer's got a new acronym for growth -- FAAA.

Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy

Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy

A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.

Bristol-Myers Squibb And Nektar Therapeutics Announce Oncology Clinical Collaboration To Evaluate The Combination Of Opdivo (nivolumab) And NKTR-214

Bristol-Myers Squibb And Nektar Therapeutics Announce Oncology Clinical Collaboration To Evaluate The Combination Of Opdivo (nivolumab) And NKTR-214

Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq:NKTR) today announced a new clinical collaboration to evaluate Bristol-Myers Squibb's Opdivo (nivolumab) with Nektar's investigational...

Amgen Multiple Myeloma Drug Kyprolis Fails to Help Newly Diagnosed Patients

Amgen Multiple Myeloma Drug Kyprolis Fails to Help Newly Diagnosed Patients

Amgen's effort to improve disappointing sales of its multiple myeloma drug Kyprolis took a hit Tuesday with the failure of a phase III clinical trial involving newly diagnosed patients.

Weekly Roundup

With the Fed decision behind it, the market focuses on earnings and oil. In the portfolio, we added to three positions and exited from one.

Bristol-Myers Squibb Stock Is Down, but That Means You Should Buy

Bristol-Myers Squibb Stock Is Down, but That Means You Should Buy

This drug stock has stumbled on a failed clinical trial, but here's why the stock is a bargain right now.

Bristol-Myers Squibb To Take Part In Leerink Partners Immuno-Oncology Roundtable Conference

Bristol-Myers Squibb To Take Part In Leerink Partners Immuno-Oncology Roundtable Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in Leerink Partners Immuno-Oncology Roundtable Conference on Thursday, September 29, 2016, in New York.

Bristol-Myers' 'Green Shoots' Say Don't Play the Short Side

Bristol-Myers' 'Green Shoots' Say Don't Play the Short Side

A quick-turning reversal pattern is all that is needed to set things in motion.

European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application For Opdivo (nivolumab) In Advanced Form Of Bladder Cancer

European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application For Opdivo (nivolumab) In Advanced Form Of Bladder Cancer

Bristol-Myers Squibb Company (NYSE:BMY) announced today that the European Medicines Agency (EMA) validated its type II variation application, which seeks to extend the current indications for Opdivo to include the...

Bristol-Myers Squibb Awards First

Bristol-Myers Squibb Awards First "Golden Tickets" For LabCentral To PanTher, Suono Bio

Bristol-Myers Squibb Company (NYSE:BMY) and LabCentral, an innovative, shared laboratory space designed as a launch pad for life-sciences and biotech startups, today announced that PanTher and Suono Bio are the...

Pull Those Stocks Up!

The market is just plain droopy.

Weekly Roundup

The market gets pushed and pulled by the Fed, oil and loads of economic reports. Meanwhile, the portfolio includes a new name.

Jim Cramer's Top Takeaways: Bristol-Myers Squibb, Toll Brothers, Foot Locker

Jim Cramer's Top Takeaways: Bristol-Myers Squibb, Toll Brothers, Foot Locker

Cramer says Bristol-Myers is the value stock to own and Foot Locker is doing as well as he predicted.

Jim Cramer's 'Mad Money' Recap: Strong Demand Keeps Market From Cratering

Jim Cramer's 'Mad Money' Recap: Strong Demand Keeps Market From Cratering

Demand is quite healthy and markets are not going into the abyss, Cramer says.

Bristol-Myers (BMY) Stock Price Target Lowered at Jefferies

Bristol-Myers (BMY) Stock Price Target Lowered at Jefferies

Bristol-Myers' (BMY) stock price target was cut to $57 at Jefferies on Monday.

Weekly Roundup

Oil, Fed chatter throw a wrench in the end of the week. In the portfolio, we add to 2 names and drop another.

Bristol-Myers: The Pattern Is Back

2 ways to play it -- aggressive or conservative -- as the bullish crossover returns.

Bristol-Myers Squibb To Announce Results For Third Quarter 2016 On October 27

Bristol-Myers Squibb To Announce Results For Third Quarter 2016 On October 27

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2016 on Thursday, October 27, 2016.

Bristol-Myers Squibb To Present At Bank Of America Merrill Lynch Global Health Care Conference

Bristol-Myers Squibb To Present At Bank Of America Merrill Lynch Global Health Care Conference

Bristol-Myers Squibb Company (NYSE:BMY) will present at the Bank of America Merrill Lynch Global Health Care Conference on Wednesday, September 14, 2016, in London.

Bristol-Myers Squibb Employees Cycle Coast To Coast To Raise Money And Awareness For Cancer Research

Bristol-Myers Squibb Employees Cycle Coast To Coast To Raise Money And Awareness For Cancer Research

Today, the first of six teams of Bristol-Myers Squibb Company (NYSE:BMY) oncology employees set out from Cannon Beach on the Oregon coast on the first leg of the 2016 Coast 2 Coast 4 Cancer Ride , a 21-day cycling ride...

What Facebook, Ford Have in Common

What Facebook, Ford Have in Common

The major indexes may have been flat during the month of August, but there was a lot of buying under the surface, especially in popular stocks like Facebook and Ford.

Bristol-Myers Squibb (BMY) Stock Gains on EU Drug Approval

Bristol-Myers Squibb (BMY) Stock Gains on EU Drug Approval

The European Commission approved Bristol-Myers Squibb's (BMY) Orencia rheumatoid arthritis drug on Tuesday for use in patients that have not yet been treated with methotrexate.

Bristol-Myers Squibb To Take Part In Morgan Stanley Global Health Care Conference

Bristol-Myers Squibb To Take Part In Morgan Stanley Global Health Care Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Morgan Stanley 2016 Global Health Care Conference on Tuesday, September 13, 2016, in New York.

European Commission Approves Bristol-Myers Squibb's ORENCIA® (abatacept) For The Treatment Of Highly Active And Progressive Disease In Adult Patients With Rheumatoid Arthritis Not Previously Treated With Methotrexate

European Commission Approves Bristol-Myers Squibb's ORENCIA® (abatacept) For The Treatment Of Highly Active And Progressive Disease In Adult Patients With Rheumatoid Arthritis Not Previously Treated With Methotrexate

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission has approved ORENCIA ® (abatacept) intravenous (IV) infusion and subcutaneous (SC) injection, in combination with...

Weekly Roundup

The market stayed in a narrow range as oil, the Fed and jobs took the headlines. We added to 2 portfolio positions.

What the Jobs Reports Means for the Market and the Portfolio

A breakdown of today's nonfarm payrolls and where the portfolio stands going into the Labor Day weekend.

Adding to Bristol-Meyers on Weakness

There will be some near-term volatility, but we view the investment as a contrarian opportunity.